Neurology:卒中后,远程康复疗法效果不输于常规康复方法

2020-12-26 Freeman MedSci原创

运动功能障碍是中风致残最突出的症状,并已导致沉重的社会和经济负担。但缺乏医院康复资源、设施,会造成脑卒中患者无法得到良好的康复治疗。因此,发现有效、可用的脑中风康复方法,势在必行。

运动功能障碍是中风致残最突出的症状,并已导致沉重的社会和经济负担。但缺乏医院康复资源、设施,会造成脑卒中患者无法得到良好的康复治疗。因此,发现有效、可用的脑中风康复方法,势在必行。
 
以家庭为基础的远程康复(Home-based telerehabilitation,TR)是一种康复程序,藉此康复医生能通过电信设备为残疾患者提供康复疗法。之前的结果表明,TR 方法在改善日常生活活动能力(IADL)和提高康复训练依从性方面与常规康复方法(CR)效果相当。结构和功能MRI能让我们理解脑卒中康复过程中结构神经塑性改变(structure neuroplastic alterations),脑卒中后的运动恢复与初级运动皮质结构重组、皮质脊髓束修复和大脑半球间M1区功能重组高度相关。
 
复旦大学附属中山医院的Jing Chen等人,结合运动功能评估和多模态磁共振成像分析方法,探讨皮层下脑中风发作后,为期12周的远程家庭康复疗法对患者的康复效果的影响。
 
他们将52例脑卒中偏瘫患者随机分为家庭康复训练组(TR 组)和常规康复训练组(CR 组) ,治疗12周。采用 Fugl-Meyer 评估(FMA)上肢和下肢感觉运动功能,并把改良的Barthel 指数(MBI)作为主要结局。次要结局:包括双侧 M1区之间的静息状态功能连接性(rsFC)、初级运动皮质区(M 1)的灰质体积和锥体束(CST)的白质完整性。
 
结果显示: 与 CR 组相比,TR 组 FMA 明显改善(p = 0.011) ,M1-M1 rsFC 明显增加(p = 0.031)。TR 组 两侧M1-M1之间 rsFC 变化与 FMA 变化呈显著正相关(p = 0.018)。
 
本研究的重要临床意义在于,家庭远程康复计划对脑卒中患者的运动功能恢复颇有好处,同时伴随着 M1区域的大脑半球功能连通性的增强。这提示脑卒中患者在家接受专业的康复训练是可行的、安全的、有效的。

原始出处:

Neurology Oct 2020, 95 (17) e2318-e2330; DOI: 10.1212/WNL.0000000000010821

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671415, encodeId=bda916e14156d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Jun 30 00:02:53 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001176, encodeId=427820011e6b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 14 01:02:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912048, encodeId=cbdb912048bd, content=转发, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:51:12 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911380, encodeId=5c8a91138068, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Dec 27 20:23:19 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911178, encodeId=e1749111e8f1, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>不断学习新知识,加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sat Dec 26 23:48:19 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911030, encodeId=c296911030da, content=很实用,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bb01447780, createdName=562762626, createdTime=Sat Dec 26 09:42:45 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911029, encodeId=2ac3911029e4, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/d1f232a1b61443dc893e8ff95474e60b/7ad7474277f6427eb1c2305a87e1c4b2.jpg, createdBy=1a665432979, createdName=Lydia-1110, createdTime=Sat Dec 26 09:19:51 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026732, encodeId=7bb21026e32bd, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047250, encodeId=4b09104e25001, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671415, encodeId=bda916e14156d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Jun 30 00:02:53 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001176, encodeId=427820011e6b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 14 01:02:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912048, encodeId=cbdb912048bd, content=转发, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:51:12 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911380, encodeId=5c8a91138068, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Dec 27 20:23:19 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911178, encodeId=e1749111e8f1, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>不断学习新知识,加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sat Dec 26 23:48:19 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911030, encodeId=c296911030da, content=很实用,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bb01447780, createdName=562762626, createdTime=Sat Dec 26 09:42:45 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911029, encodeId=2ac3911029e4, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/d1f232a1b61443dc893e8ff95474e60b/7ad7474277f6427eb1c2305a87e1c4b2.jpg, createdBy=1a665432979, createdName=Lydia-1110, createdTime=Sat Dec 26 09:19:51 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026732, encodeId=7bb21026e32bd, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047250, encodeId=4b09104e25001, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2021-04-14 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1671415, encodeId=bda916e14156d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Jun 30 00:02:53 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001176, encodeId=427820011e6b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 14 01:02:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912048, encodeId=cbdb912048bd, content=转发, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:51:12 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911380, encodeId=5c8a91138068, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Dec 27 20:23:19 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911178, encodeId=e1749111e8f1, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>不断学习新知识,加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sat Dec 26 23:48:19 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911030, encodeId=c296911030da, content=很实用,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bb01447780, createdName=562762626, createdTime=Sat Dec 26 09:42:45 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911029, encodeId=2ac3911029e4, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/d1f232a1b61443dc893e8ff95474e60b/7ad7474277f6427eb1c2305a87e1c4b2.jpg, createdBy=1a665432979, createdName=Lydia-1110, createdTime=Sat Dec 26 09:19:51 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026732, encodeId=7bb21026e32bd, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047250, encodeId=4b09104e25001, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2020-12-30 124764c3m24(暂无昵称)

    转发

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1671415, encodeId=bda916e14156d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Jun 30 00:02:53 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001176, encodeId=427820011e6b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 14 01:02:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912048, encodeId=cbdb912048bd, content=转发, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:51:12 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911380, encodeId=5c8a91138068, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Dec 27 20:23:19 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911178, encodeId=e1749111e8f1, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>不断学习新知识,加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sat Dec 26 23:48:19 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911030, encodeId=c296911030da, content=很实用,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bb01447780, createdName=562762626, createdTime=Sat Dec 26 09:42:45 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911029, encodeId=2ac3911029e4, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/d1f232a1b61443dc893e8ff95474e60b/7ad7474277f6427eb1c2305a87e1c4b2.jpg, createdBy=1a665432979, createdName=Lydia-1110, createdTime=Sat Dec 26 09:19:51 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026732, encodeId=7bb21026e32bd, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047250, encodeId=4b09104e25001, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2020-12-27 易水河

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1671415, encodeId=bda916e14156d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Jun 30 00:02:53 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001176, encodeId=427820011e6b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 14 01:02:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912048, encodeId=cbdb912048bd, content=转发, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:51:12 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911380, encodeId=5c8a91138068, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Dec 27 20:23:19 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911178, encodeId=e1749111e8f1, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>不断学习新知识,加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sat Dec 26 23:48:19 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911030, encodeId=c296911030da, content=很实用,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bb01447780, createdName=562762626, createdTime=Sat Dec 26 09:42:45 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911029, encodeId=2ac3911029e4, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/d1f232a1b61443dc893e8ff95474e60b/7ad7474277f6427eb1c2305a87e1c4b2.jpg, createdBy=1a665432979, createdName=Lydia-1110, createdTime=Sat Dec 26 09:19:51 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026732, encodeId=7bb21026e32bd, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047250, encodeId=4b09104e25001, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2020-12-26 医路顺丰

    #学习#不断学习新知识,加油!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1671415, encodeId=bda916e14156d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Jun 30 00:02:53 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001176, encodeId=427820011e6b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 14 01:02:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912048, encodeId=cbdb912048bd, content=转发, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:51:12 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911380, encodeId=5c8a91138068, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Dec 27 20:23:19 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911178, encodeId=e1749111e8f1, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>不断学习新知识,加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sat Dec 26 23:48:19 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911030, encodeId=c296911030da, content=很实用,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bb01447780, createdName=562762626, createdTime=Sat Dec 26 09:42:45 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911029, encodeId=2ac3911029e4, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/d1f232a1b61443dc893e8ff95474e60b/7ad7474277f6427eb1c2305a87e1c4b2.jpg, createdBy=1a665432979, createdName=Lydia-1110, createdTime=Sat Dec 26 09:19:51 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026732, encodeId=7bb21026e32bd, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047250, encodeId=4b09104e25001, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2020-12-26 562762626

    很实用,值得学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1671415, encodeId=bda916e14156d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Jun 30 00:02:53 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001176, encodeId=427820011e6b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 14 01:02:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912048, encodeId=cbdb912048bd, content=转发, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:51:12 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911380, encodeId=5c8a91138068, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Dec 27 20:23:19 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911178, encodeId=e1749111e8f1, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>不断学习新知识,加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sat Dec 26 23:48:19 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911030, encodeId=c296911030da, content=很实用,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bb01447780, createdName=562762626, createdTime=Sat Dec 26 09:42:45 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911029, encodeId=2ac3911029e4, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/d1f232a1b61443dc893e8ff95474e60b/7ad7474277f6427eb1c2305a87e1c4b2.jpg, createdBy=1a665432979, createdName=Lydia-1110, createdTime=Sat Dec 26 09:19:51 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026732, encodeId=7bb21026e32bd, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047250, encodeId=4b09104e25001, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2020-12-26 Lydia-1110

    不错

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1671415, encodeId=bda916e14156d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Jun 30 00:02:53 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001176, encodeId=427820011e6b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 14 01:02:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912048, encodeId=cbdb912048bd, content=转发, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:51:12 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911380, encodeId=5c8a91138068, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Dec 27 20:23:19 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911178, encodeId=e1749111e8f1, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>不断学习新知识,加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sat Dec 26 23:48:19 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911030, encodeId=c296911030da, content=很实用,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bb01447780, createdName=562762626, createdTime=Sat Dec 26 09:42:45 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911029, encodeId=2ac3911029e4, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/d1f232a1b61443dc893e8ff95474e60b/7ad7474277f6427eb1c2305a87e1c4b2.jpg, createdBy=1a665432979, createdName=Lydia-1110, createdTime=Sat Dec 26 09:19:51 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026732, encodeId=7bb21026e32bd, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047250, encodeId=4b09104e25001, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2020-12-26 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1671415, encodeId=bda916e14156d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Jun 30 00:02:53 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001176, encodeId=427820011e6b6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 14 01:02:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912048, encodeId=cbdb912048bd, content=转发, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:51:12 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911380, encodeId=5c8a91138068, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Dec 27 20:23:19 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911178, encodeId=e1749111e8f1, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>不断学习新知识,加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201226/95ac6d022b194200b46211c8dd67d7d4/d7639abce33d42f18edacbf9c1818b2b.jpg, createdBy=1c242248512, createdName=医路顺丰, createdTime=Sat Dec 26 23:48:19 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911030, encodeId=c296911030da, content=很实用,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bb01447780, createdName=562762626, createdTime=Sat Dec 26 09:42:45 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911029, encodeId=2ac3911029e4, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/d1f232a1b61443dc893e8ff95474e60b/7ad7474277f6427eb1c2305a87e1c4b2.jpg, createdBy=1a665432979, createdName=Lydia-1110, createdTime=Sat Dec 26 09:19:51 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026732, encodeId=7bb21026e32bd, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047250, encodeId=4b09104e25001, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Dec 26 08:02:53 CST 2020, time=2020-12-26, status=1, ipAttribution=)]
    2020-12-26 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

相关资讯

新冠肺炎出院患者康复方案印发,轻重症出院后有区别性要求

国家卫健委网站3月5日消息,为进一步做好新冠肺炎出院患者的康复工作,改善患者的呼吸功能、躯体功能、心理功能、日常生活活动能力及社会参与能力,规范康复操作技术及流程。我委印发了《新冠肺炎出院患者康复方案(试行))》(以下简称《康复方案(试行)》)。《康复方案(试行)》明确了出院后患者的康复场所,如指定的康复医疗机构、社区、家庭等。同时,针对新冠肺炎出院患者主要发生的呼吸功能、躯体功能、心理功能、

扩散!新冠肺炎康复者血浆捐献倡议书

(倡议书全文附后) ▼ 疫情发生以来,我们每天都会去关注那组“数字”,焦虑数字的增长,也欣慰看到越来越多的患者被治愈。 在目前缺乏疫苗和特效药的前提下,新冠肺炎康复者恢复期的血浆是临床特异性治疗最可及的资源。 2月5日国家卫生健康委员会发布了《新型冠状病毒感染的肺炎诊疗方案(试行第五版)》,提出“可采用恢复期血浆治疗”。 由国药中国生物承担的“2019-nCoV感染恢复期患者

新冠感染者精液核酸检测阳性,包含康复期患者:传染性待研究

科学家仍在密切关注新型冠状病毒对男性生殖系统的影响。一个中国联合研究团队首次在38名男性新冠患者的精液中发现了6例阳性样本,其中2例来自康复期患者,令这种关注更具现实性。

外媒:英德两国考虑向新冠肺炎康复患者颁发“免疫证书”

近日,英国与德国考虑向新冠肺炎康复患者颁发“免疫证书”,以此证明其对新冠病毒具有免疫力,从而免于活动限制。

重磅突破!华东师大新增医学类本科专业:听力与言语康复学

日前,教育部印发了《关于公布2019年度普通高等学校本科专业备案和审批结果的通知》(教高函〔2020〕2号)。在医学院筹建办公室、教育学部教育康复学系和教务处的共同努力下,华东师范大学2019年申请增设的【听力与言语康复学专业】通过教育部备案(详见下表)。截止目前,华东师范大学本科专业共有84个,招生专业73个。这是华东师范大学开设的首个医学门类本科专业,将列入2020年度本科招生计划。 

JAMA:部分新冠肺炎患者出院5-13天后又检测出新冠病毒,武汉大学中南医院发布首份新冠肺炎康复患者随访信息

今天,武汉大学中南医院影像科主任徐海波和检验科主任李一荣等,在JAMA上发表文章,报告了4例康复患者的随访信息。